SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-21-004264
Filing Date
2021-11-12
Accepted
2021-11-12 08:20:17
Documents
15
Period of Report
2021-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lyel-20211112.htm   iXBRL 8-K 53110
2 EX-99.1 lyel-ex99_1.htm EX-99.1 300263
3 GRAPHIC img227875313_0.jpg GRAPHIC 74529
  Complete submission text file 0000950170-21-004264.txt   620429

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lyel-20211112_lab.xml EX-101.LAB 16907
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lyel-20211112_def.xml EX-101.DEF 13459
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lyel-20211112.xsd EX-101.SCH 2921
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lyel-20211112_pre.xml EX-101.PRE 12781
8 EXTRACTED XBRL INSTANCE DOCUMENT lyel-20211112_htm.xml XML 5717
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

IRS No.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 211399866
SIC: 2834 Pharmaceutical Preparations